PE46197A1 - METHOD TO DECREASE THE RISK OF VERTEBRAL AND NON-VERTEBRAL FRACTURES - Google Patents
METHOD TO DECREASE THE RISK OF VERTEBRAL AND NON-VERTEBRAL FRACTURESInfo
- Publication number
- PE46197A1 PE46197A1 PE00009596A PE00009596A PE46197A1 PE 46197 A1 PE46197 A1 PE 46197A1 PE 00009596 A PE00009596 A PE 00009596A PE 00009596 A PE00009596 A PE 00009596A PE 46197 A1 PE46197 A1 PE 46197A1
- Authority
- PE
- Peru
- Prior art keywords
- vertebral
- risk
- decrease
- alendronate
- women
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
QUE APLICADO EN MUJERES OSTEROPOROSICAS, COMPRENDE ADMINISTRAR ORALMENTE UNA CANTIDAD DIARIA DE 5 mg A 20 mg DE ALENDRONATO O UNA SAL FARMACEUTICAMENTE ACEPTABLE POR UN PERIODO DE AL MENOS TRES ANOS; CUANDO SE ADMINISTRA ORALMENTE ANTES DE LA FRACTURA EN UNA DOSIS DIARIA Y POR UN PERIODO SIMILAR A LO ANTERIOR EL ALENDRONATO PUEDE REDUCIR LA SEVERIDAD DE LA FRACTURA; ADEMAS PUEDE REDUCIR LA DEFORMACION COLUMNAR Y LA PERDIDA DE ALTURA EN MUJERES OSTEOPOROSICAS MEDIANTE ADMINISTRACION ORALWHICH APPLIED TO WOMEN WITH OSTEROPOROSICS, IT INCLUDES ORALLY ADMINISTERING A DAILY AMOUNT OF 5 mg TO 20 mg OF ALENDRONATE OR A PHARMACEUTICALLY ACCEPTABLE SALT FOR A PERIOD OF AT LEAST THREE YEARS; WHEN IT IS ORALALLY ADMINISTERED BEFORE FRACTURE IN A DAILY DOSE AND FOR A PERIOD SIMILAR TO THE ABOVE, ALENDRONATE CAN REDUCE THE SEVERITY OF FRACTURE; FURTHER IT CAN REDUCE THE COLUMNARY DEFORMATION AND THE LOSS OF HEIGHT IN OSTEOPOROSIC WOMEN BY ORAL ADMINISTRATION
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39046295A | 1995-02-17 | 1995-02-17 | |
US08/389,860 US20010051616A1 (en) | 1995-02-17 | 1995-02-17 | Method of lessening the risk of vertebral fractures |
US41963195A | 1995-04-10 | 1995-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE46197A1 true PE46197A1 (en) | 1997-11-28 |
Family
ID=27409915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE00009596A PE46197A1 (en) | 1995-02-17 | 1996-02-12 | METHOD TO DECREASE THE RISK OF VERTEBRAL AND NON-VERTEBRAL FRACTURES |
Country Status (9)
Country | Link |
---|---|
AR (1) | AR002707A1 (en) |
CO (1) | CO4920257A1 (en) |
CZ (1) | CZ259097A3 (en) |
DZ (1) | DZ1991A1 (en) |
HR (1) | HRP960080A2 (en) |
IL (1) | IL117077A (en) |
PE (1) | PE46197A1 (en) |
TW (1) | TW453880B (en) |
YU (1) | YU8896A (en) |
-
1996
- 1996-02-08 IL IL11707796A patent/IL117077A/en unknown
- 1996-02-12 PE PE00009596A patent/PE46197A1/en not_active Application Discontinuation
- 1996-02-13 CZ CZ972590A patent/CZ259097A3/en unknown
- 1996-02-14 DZ DZ960032A patent/DZ1991A1/en active
- 1996-02-14 AR ARP960101382A patent/AR002707A1/en not_active Application Discontinuation
- 1996-02-15 CO CO96007058A patent/CO4920257A1/en unknown
- 1996-02-16 YU YU8896A patent/YU8896A/en unknown
- 1996-02-16 HR HRP960080 patent/HRP960080A2/en not_active Application Discontinuation
- 1996-02-28 TW TW085102340A patent/TW453880B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL117077A0 (en) | 1996-06-18 |
IL117077A (en) | 2002-08-14 |
YU8896A (en) | 1999-12-27 |
TW453880B (en) | 2001-09-11 |
HRP960080A2 (en) | 1997-10-31 |
DZ1991A1 (en) | 2002-07-20 |
CZ259097A3 (en) | 1997-11-12 |
AR002707A1 (en) | 1998-04-29 |
CO4920257A1 (en) | 2000-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2170069T3 (en) | 1-ALFA-HYDROXIPREVITAMINE D FOR ORAL ADMINISTRATION. | |
ES2188782T3 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING DARIFENACINE. | |
CU23468B7 (en) | DOSAGE FORM OF PRAMIPEXOL IN A SINGLE DAILY DOSE | |
DK0833643T3 (en) | Formulations of anhydrous monosodium salt of alendronate and their use in the treatment of bone disorders | |
RU94046316A (en) | Use of high effective phosphonates for preparing medicinal agents for osteoporosis treatment | |
BR9909672A (en) | use of an active medicinal compound in the preparation of a medicament for the treatment of hypertension | |
ES2096781T3 (en) | COMPOSITIONS OF CONTROLLED RELEASE OXICODONS. | |
BR9405843A (en) | Process to reduce bone loss and use of a compound | |
RU2008103617A (en) | BISPHOSPHONIC ACIDS INTENDED FOR TREATMENT AND PREVENTION OF OSTEOPOROSIS | |
CY2512B1 (en) | Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application | |
AR020803A1 (en) | A COMPOSITION THAT INCLUDES FEXOFENADINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINE | |
RU2003105159A (en) | METHOD FOR TREATING CLIMACTERIC DISORDERS IN WOMEN DURING OR AFTER MENOPAUSE | |
BR0114100A (en) | Controlled release formulations for oral administration | |
CA2416480A1 (en) | Method for the treatment of climacteric disorders in women during or after the menopause | |
CO5540323A2 (en) | ORAL ADMINISTRATION OF HORMONE PARATIROIDES AND CALCITONINE | |
ES2175663T3 (en) | SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MILTEPHOSINE FOR ORAL ADMINISTRATION IN THE TREATMENT OF LESHMANIASIS. | |
AR037524A1 (en) | DOSAGE UNIT INCLUDING A PROSTAGLANDINE ANALOG FOR THE CONSTIPATION TREATMENT | |
NO962752L (en) | Use of 2,3-diaryl-1-benzopyran derivatives in the manufacture of a medicament for the treatment and prevention of bone loss and osteoporosis | |
AR035946A1 (en) | PHARMACEUTICAL COMPOSITIONS TO USE IN THE TREATMENT OF DISORDERS IN WOMEN PERIMENOPAUSIC, MENOPAUSIC OR POSMENOPAUSIC, AND USES OF SUCH COMPOSITIONS FOR THE PREPARATION OF MEDICINES | |
ES2115571T3 (en) | USE OF PENTOSANA POLISULFATE FOR THE RESOLUTION OF SCARS IN CHRONIC PROGRESSIVE VASCULAR DISEASES. | |
CA2497353A1 (en) | Method for preventing or reducing secondary fractures after hip fracture | |
PE46197A1 (en) | METHOD TO DECREASE THE RISK OF VERTEBRAL AND NON-VERTEBRAL FRACTURES | |
US5914099A (en) | Prevention of tooth loss by the administration of alendronate or its salts | |
RU2003100081A (en) | METHODS AND COMPOSITIONS IN WHICH SULODEXIDE IS USED FOR THE TREATMENT OF DIABETIC NEPHROPATHY | |
US20050101673A1 (en) | Use of orally available prostacyclin derivatives for the production of a pharmaceutical agent for treating diseases that are associated with bone marrow edemas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |